API | fallypride

fallypride Report issue

Small molecule Experimental

AACT MeSH PubChem

Active Ingredient History

NOW

Fallypride is a high affinity dopamine D2/D3 receptor antagonist used in medical research, usually in the form of fallypride (18F) as a positron emission tomography (PET) radiotracer in human studies. ^Wikipedia

Chemistry

SMILES: C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCF)cc(OC)c1OC
InChIKey: OABRYNHZQBZDMG-INIZCTEOSA-N
Mol. Mass: 364.46
ALogP: 2.99 Partition coefficient
ChEMBL Molecule:
fallypride

More Chemistry

Pharmacology

Mechanisms of Action:
- D(2) dopamine receptor (Homo sapiens) ^UniProt
- D(3) dopamine receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

5-(3-fluoropropyl)-2,3-dimethoxy-n-(((2s)-1-(2-propenyl)-2-pyrrolidinyl)methyl)benzamide | fallypride

Organizations (6)

Research & Development (6)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)

Analgesics, Opioid (Phase 3)

Healthy Volunteers (Phase 2)

Obesity (Phase 2)

Obesity, Morbid (Phase 1)

Opioid-Related Disorders (Phase 3)

Overweight (Early Phase 1)

Schizophrenia (Phase 1)

Substance Withdrawal Syndrome (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 6
# of Trial Organizations: 6

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue